Bayer stock is humming today on rumors that Novartis will mount a buyout of the giant German pharma company. European wire services quoted an offering price of €70 per share (about $94), citing anonymous traders--and giving investors plenty of room to buy Bayer stock. The company currently has a market value of $56.5 billion and the supposed Novartis offer would value it at $73.1 billion.

Adding fuel to the rumors, a Novartis spokesman offered a mere "no comment" rather than a "no" when asked about a Bayer offer. And flush with the cash [1] it got from its sale of Gerber to Nestle, the company has said it's looking at possible acquisitions. But some pharmaceuticals analysts said a deal seemed unlikely. Bayer only just completed its acquisition of Schering [2], for one thing, and the quoted price seems a bit high. 

- read the report [3] from MarketWatch

Related Articles:
NCI cancels Novartis cancer study. Report [3]
Australia bans Novartis' Prexige. Report [3]
Novartis shares slide after Zelnorm gets yanked. Report [4]
Bayer plans to beef up biotech pipeline. Report [5]